UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo UK Medical Research Logo Leeds University Logo Liverpool University Logo Newcastle University Logo Sheffield University Logo
UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo

Leeds Liverpool Newcastle Sheffield

MRC DiMeN Doctoral Training Partnership

Discovery Medicine North

Current Opportunities

Thank you for your interest in DiMeN DTP PhD studentships, the formal online application system for October 2021 is now closed. 

We put student choice at the heart of our Doctoral Training Partnership with an amazing range of projects for you to choose for PhD study.  Research topics include cardiovascular disease, neuroscience, bioinformatics, virology, immunology, microbiology, antibiotic resistance, ageing and many more. Projects with industry partners (iCASE) offer a unique opportunity undertake translational research. Example titles and abstracts for 2021 entry are  below for reference.

 

Equality, diversity and inclusion statement

The DiMeN DTP partners are wholly committed to increasing the diversity of individuals undertaking research and to ensuring that they do so in a supportive and inclusive training environment. Diversity strengthens our research community, we actively encourage applicants from diverse career paths and backgrounds and from all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status. All appointments are made on merit and our shortlisting to interview process is conducted blindly to ensure fairness and consistency to everyone who applies.

Click the title links below to read more detail about each PhD project (more links are going live daily as the team work to upload abstracts to FindAPhD!)

iCASE projects with an industry partner, enhanced stipend and 3 month placement:

iCASE 6: Elucidating new redox-signalling mechanisms that act to maintain healthy tissues during ageing (Newcastle: Dr Elizabeth Veal and iCASE partner: Nuchido)

iCASE 7: Understanding dysregulated repair in lung disease through precise laser injury and quantitative analysis of live cell behaviours in a human airway epithelial model (Newcastle: Prof Christopher Ward and iCASE partner: Boehringer Ingelheim)

iCASE 10: Investigating the effect of kidney disease on cardiovascular system and the therapeutic potential of a cell therapy (Liverpool: Prof Patricia Murray and iCASE partner: Nano Biosols)

iCASE 12: Effects of SARS-CoV-2 on blood vessels (Newcastle: Prof Simi Ali and iCASE partner: Akari Therapeutics)

iCASE 13: Smoking gun or faulty safety switch? Investigating the mechanism of cardiovascular damage in COVID-19  (Sheffield: Dr Izzy Jayasinghe and Badrilla Ltd)

iCASE 14: Development and understanding modes of action of novel inhibitors of RNA polymerase effective against multi-drug-resistant Mycobacterium tuberculosis (Newcastle: Prof Nikolay Zenkin and Demuris Ltd)

iCASE 15: In vivo characterisation and optimisation of a novel engineered micro pancreas (EMP) for supporting clinical translation in diabetes treatment (Leeds: Dr Xuebin Yang and Betalin Therapeutics)

iCASE 16: The drugs don’t work: Developing a combined magnetic tweezers and TIRF-FRET platform to investigate the mechanopharmacology of DNA repair inhibitors (Sheffield: Dr Tim Craggs and Cairn Research)

iCASE 17: Targeted assays for screening and treatment stratification of COVID-19 and other viral infections (Liverpool: Prof Claire Eyers and Thermo Fisher Scientific)

iCASE 18: Diagnosing by eye: using machine learning to unlock the power of retinal imaging for improving healthcare (Prof Jenny Read and Neura Health Group)

iCASE 19: The development of physiologically and clinically relevant liver models for drug screening and development (Liverpool: Prof Chris Goldring and Manchester BIOGEL)

iCASE 21: Synthesis, characterisation and medical applications of photoluminescent biocompatible gold nanoclusters (Newcastle: Prof Christopher Dennison and Nanoco Technologies Ltd)

iCASE 22: In vitro characterisation of a novel Engineered Micro-Pancreas (EMP) and identification of prognostic biomarkers towards evidence-based, safe, and effective clinical implementation (Newcastle: Dr Bill Scott and Betalin Therapeutics)

 

---------

Standard 2: Understanding recognition of enterococcal cell surface by bacteriophages to produce genetically modified phages as novel therapeutics (Sheffield: Dr Stéphane Mesnage)

Standard 3: Dysregulation of non-coding RNAs in the development of Hepatocellular carcinoma (Leeds: Prof Ade Whitehouse)

Standard 4:  A molecular understanding of the outer membrane protein assembly pathway in gram negative bacteria to underpin the discovery of new antibiotic targets (Leeds: Dr Anton Calabrese)

Standard 5:  Using targeted protein degradation to analyse the gene expression mechanisms that drive breast cancer (Newcastle: Prof David Elliott)

Standard 6:  Assembly of a bacterial killing machine (Newcastle: Prof Tracy Palmer)

Standard 7:  The genetics and genomics of rare disease: Joubert syndrome and the ciliopathies (Newcastle: Prof John Sayer)

Standard 8:  Deciphering mechanisms underpinning age related auditory neuropathy (Sheffield: Dr Mirna Mustapha)

Standard 9:  A nanoscale view of replication – tackling tricky topologies to kill cancer cells (Sheffield: Dr Alice Pyne)

Standard 11:  Using artificial intelligence to optimise treatment decisions by analysis of retinal images for patients with blinding diabetic eye disease (Newcastle: Prof Boguslaw Obara)

Standard 12:  Determining the influence of diet and the gut microbiome in preterm infant health and disease (Newcastle: Dr Christopher Stewart)

Standard 13:  Visualising the molecular assembly of perineuronal nets by super-resolution microscopy in ageing brains (Leeds: Dr Jessica Kwok)

Standard 15: Finding new drugs to target heart attack and stroke (Sheffield: Prof Paul Evans)

Standard 16: How does the regulation of macropinocytosis control cancer growth and metastasis? (Sheffield: Dr Elena Rainero)

Standard 18:  Physics-informed neural networks for predicting patient anatomical motion during radiotherapy (Leeds: Dr Zeike Taylor)

Standard 19:  Towards specialised treatments for childhood-onset neurological diseases caused by abnormal RNA metabolism (Newcastle: Dr Claudia Schneider)

Standard 20: Using the metabolome to optimize exercise as a therapeutic strategy in the ageing diabetes patient (Leeds: Dr Lee Roberts)

Standard 21: Identification of disease mechanisms and novel therapeutic targets in Charcot-Marie-Tooth disease (Sheffield: Dr Andrew Grierson)

Standard 23: Falling into place: a novel approach to phenotyping falls in early Parkinson’s disease (Newcastle: Dr Alison Yarnall)

Standard 24: Decision-making and cognitive plasticity in autism spectrum disorders (Newcastle: Dr Abhishek Banerjee)

Standard 27: Is your heart ageing faster than the rest of you? Is inflammation-related cardiac disease making your heart age faster than it should? (Liverpool: Prof Gregory Lip)

Standard 28: Combating drug resistance with evolutionary biology (Newcastle: Dr Sergey Melnikov)

Standard 29: Neuroinflammation in Alzheimer’s disease: what is the role of amyloid-beta fibril structure? (Leeds: Dr Eric Hewitt)

Standard 30: Dissecting the interactome between enteric viruses and the gut microbiota for therapeutic discovery (Leeds: Dr Morgan Herod)

Standard 31: Nutrition, ageing and prostate cancer: an experimental approach using Drosophila (Liverpool: Dr Stuart Wigby)

Standard 33: Cell painting: Illuminating the whole cell to develop treatments for mitochondrial disease (Newcastle: Dr Oliver Russell)

Standard 36: Modelling antibiotic resistance in chronic Pseudomonas aeruginosa infections (Liverpool: Dr Jo Fothergill)

Standard 39: Investigating cellular senescence in the tumour microenvironment as a determinant of treatment response in head and neck cancer (Liverpool: Prof Christian Ottensmeier)

Standard 40: Mapping mitochondrial genome instability in mitochondrial disease (Newcastle: Dr Thomas Nicholls)

Standard 41: Discovery of B and plasma cell biology through the prism of primary immunodeficiencies (Leeds: Dr Sinisa Savic)

Standard 42: The identification and optimisation of small molecule inhibitors of PfAPP as a novel antimalarial strategy (Leeds: Dr Richard Foster)

Standard 44: Mechanisms of synapse loss during neurodegeneration and ageing (Liverpool: Dr Natalia Sanchez Soriano)

Standard 48: Using imaging genomics to unlock the door to better treatments for osteoarthritis  (Sheffield: Prof Mark Wilkinson)

Standard 49: UCHL1 inhibition – a strategy to target aberrant HIF signalling in fibrotic liver disease? (Liverpool: Dr Niall Kenneth)

Standard 50: Mechanism of replication proofreading by SARS-CoV-2 (Newcastle: Dr Yulia Yuzenkova)

Standard 51: Caught in the act. Protease capture technologies to understand immune cell function in inflammatory disease (Sheffield: Prof Simon Jones)

Standard 52: To kill and cure: Understanding antibiotic action to enhance activity (Sheffield: Prof Simon Foster)

Any questions regarding DiMeN please contact the DTP team: dimen.dtp@sheffield.ac.uk